Table 3.

Docosahexanoic acid (DHA) supplementation protocols and omega-3 index (O3i).

References	Supplementation protocol	Participants	Baseline O3i (%)	Final O3i (%)
Klingel et al. (39) B	3,000 mg/day DHA (TAG) for 12 wks	N = 30 young, healthy adults (50% male) mean age 22 ± 2 yrs (Canada)	3.5 ± 0.1	8.4 ± 0.2*
Lee et al. (10) B	3,256 mg/d DHA for 12 wks	N = 28 young, healthy adults (50% male) mean age 22 ± 2 yrs (Canada)	3.6 ± 0.1	8.4*#
Mazahery et al. (44)	722 mg/d DHA for 1 yr	N = 23 children (78% male) mean age 5 ± 2 yrs with autism spectrum disorder (New Zealand)	Median: 4.7	Median: 9.1*#
Geppert et al. (45)	940 mg/d DHA for 8 wks	N = 52 healthy adult (76% female) mean age 26 ± 6 yrs vegetarians (Germany)	4.8 ± 0.2	8.4 ± 0.2*
Allaire et al. (38) B	2,700 mg/d DHA (rTAG) for 10 wks	N = 123 adults (69% female) with abdominal obesity and elevated CRP (Canada) Female mean age 50 ± 16 yrs Male mean age 57 ± 12 yrs	6.2 ± 0.1	11.7 ± 0.1*
Massari et al. (25)	200 mg/d DHA for ~ 5 mos	N = 65 pregnant, healthy females mean age 31 ± 5 yrs (Italy)	6.5 ± 1.4	8.0 ± 1.6*
Egert et al. (22) B	Fortified margarine providing 2,300 mg/d DHA for 6 wks	N = 25 healthy adults (60% female) mean age 25 ± 3 yrs (Germany)	9.4 ± 3.7	18.5 ± 4.2*

Research studies compared different doses, forms of n-3 FA, or composition; thus, each intervention protocol has a separate entry. O3i are presented as means ± SD unless otherwise noted.

^*p < 0.05;

^#calculated final O3i. TAG, triglycerides; rTAG, re-esterified triglycerides.